



AMERISE BIOSCIENCES LIMITED

CIN: L29199GJ1984PLC007195

(Formerly Known as AMRADEEP INDUSTRIES LIMITED)

Date: 08.08.2022

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Dear Sir / Madam,

Sub: Un-Audited Financial Result quarter ending 30th June, 2022 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015


Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. **Monday 8th August 2022** at the Registered Office of the Company and transacted the following major businesses:

- 1.) Considered and approved Un-audited financial results for the quarter ended as on 30th June, 2022.

Please take the above intimation in your records.

Thanking You,

Yours Faithfully,
For, AMERISE BIOSCIENCES LIMITED



DIRECTOR/AUTHORISED SIGNATORY

Amerise Biosciences Ltd

Formerly known as Amradeep Industries Limited

CIN:- L29199GJ1984PLC007195

Regd. Office: 24, Laxmi Chambers, Navjeevan Press Road, Opp. Old Gujarat High Court, Ahmedabad - 380014

Email:- amradeepindustries@gmail.com

(Rs. In lacs)

Statement of Un-audited Standalone Financial Results for the Quarter Ended June 30, 2022


Sl no.	Particulars	Quarter Ended		Year Ended	
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	INCOME				
(a)	Gross Revenue from sale of products	-	564.89	151.72	900.80
(b)	Other Operating Revenue	0.29	91.70	(2.58)	56.94
1	Revenue from Operations	0.29	656.59	149.14	957.74
2	Other Income	-	-	-	-
3	Total Income	0.29	656.59	149.14	957.74
	EXPENSES				
(a)	Cost of materials consumed	-	626.15	118.46	891.46
(b)	Purchases of Stock-in-Trade	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-
(d)	Employee benefit expense	0.71	1.20	0.69	5.31
(e)	Finance Costs	-	-	-	-
(f)	Depreciation and amortization expense	-	-	-	-
(g)	Other expenses	3.55	0.65	0.31	6.05
4	Total Expenses	4.26	628.00	119.46	902.82
5	Profit / (Loss) from operations before exceptional items Tax (1-2)	(3.97)	28.59	29.68	54.92
6	Exceptional Items	-	-	-	-
7	Profit / (Loss) before Tax (5 ± 6)	(3.97)	28.59	29.68	54.92
8	Tax Expense	-	-	-	-
9	Net Profit / (Loss) after Tax (7 - 8)	(3.97)	28.59	29.68	54.92
10	Other Comprehensive Income (net of tax)	-	-	-	-
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
11	Total Comprehensive Income for the period (9 ± 10)	(3.97)	28.59	29.68	54.92
12	Paid-up equity share capital (Face Value of Rs. 1/- each)	660.69	660.69	660.69	660.69
13	Other Equity	-	-	-	(96.77)
14	Earnings Per Share (of Rs. 1/- each) (not annualised):				
	(a) Basic	(0.01)	0.04	0.04	0.08
	(b) Diluted	(0.01)	0.04	0.04	0.08

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 08, 2022. The Statutory Auditors have carried out a limited review of the above financial result.
- Company has only one segment and hence no separate segment result has been given.
- The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Ahmedabad

Date : 08th August, 2022





Limited Review Report on unaudited standalone financial results of Amerise Biosciences Ltd for the quarter ended 30 June 2022 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Amerise Biosciences Ltd

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **Amerise Biosciences Ltd** for the quarter ended 30 June 2022 ("the Statement"), being submitted pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and is substantially less than the audit conducted in accordance with the standards on Auditing Specified under section 143(10) of the Act, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards i.e. Ind AS 34 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, BIPIN & CO.
Chartered Accountants
FRN: 101509 W


CA AMIT SHAH (Partner)

M. No.: 126337

Place: Vadodara

Date: 08/08/2022

UDIN: 22126337AONFGP9658

